Under the MSA, Scinai will provide drug development and cGMP manufacturing services, including aseptic filling and quality assurance, to Ayana, including encapsulating drug substances of various partners of Ayana into Ayana's proprietary liposomal drug delivery system.
Ayana COO
The agreement is anticipated to provide Scinai with at least
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and pre-clinical and clinical trial design and execution services to early stage biotech companies. Company website: www.scinai.com.
About Scinai Bioservices
The CDMO business unit of Scinai Immunotherapeutic Ltd, Scinai Bioservices, serves pharmaceutical and biotech companies with drug development and manufacturing services for clinical supplies. Leveraging Scinai's state-of-the-art GMP facility in
About Ayana Pharma Ltd.
Ayana Pharma Ltd is a pharmaceutical company focused on the development and manufacturing of liposomal therapeutics for the treatment of cancer and other diseases. Its flagship product, Doxorubicin HCl Liposome Injection, is FDA-approved for treatment of ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma, and is marketed in the
Contact Details
Scinai: Business Development bd@scinai.com | Investor Relations ir@scinai.com | +972 8 930 2529
Ayana:
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the anticipated revenues from the agreement with Ayana Pharmaceuticals and the potential of the Company's business, including its CDMO business. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to, the risk that some or all of the expected benefits of the agreement with Ayana Pharmaceuticals will not be achieved; the risk that the Company's business, including CDMO business, will not grow; the risk that the Company will not maintain its listing on Nasdaq; that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of NanoAbs will not be met; the risk of a delay in the preclinical and clinical trials data for NanoAbs, if any; the risk that our business strategy may not be successful; the risk that the European Investment Bank (EIB) may accelerate the loans under its finance contract with Scinai; risks relating to the SARS-CoV-2 (COVID-19) virus; Scinai's ability to acquire rights to additional product opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai's manufacturing facility in
Logo - https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg